Balancing T cell subsets could reduce chronic inflammation and promote tissue repair, offering a potential therapeutic strategy in IDD. Targeting specific cytokines and transcription factors involved in T cell differentiation (e.g., STAT3, FOXP3) could enhance therapeutic outcomes. Here, STAT3 is linked to intervertebral disk degenerative disorder.